Chikungunya as a paradigm for emerging viral diseases

Evaluating disease impact and hurdles to vaccine development

Giovanni Rezza, Scott Weaver

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Chikungunya fever (CHIKF) is an emerging infectious disease caused by an alphavirus transmitted by Aedes spp. mosquitoes. Because mosquito control programs are not highly efficient for outbreak containment, vaccines are essential to reduce the burden of disease. Although no licensed vaccine against CHIKF is yet available, many highly promising candidates are undergoing preclinical studies, and a few of them have been tested in human trials of phase 1 or 2. Here, we review recent findings regarding the need for a CHIKF vaccine and provide an update on vaccines nearing or having entered clinical trials. We also address needs to tackle bottlenecks to vaccine development-including scientific and financial barriers-and to accelerate the development of vaccines; several actions should be taken: (i) design efficacy trials to be conducted during the course of outbreaks; (ii) evaluate the opportunity for adopting the "animal rule"for demonstration of efficacy for regulatory purposes; (iii) strengthen the collective commitment of nations, international organizations, potential donors and industry; (iv) stimulate public and/or private partnerships to invest in vaccine development and licensure; and (v) identify potential markets for an effective and safe CHIKF vaccine.

Original languageEnglish (US)
Pages (from-to)e0006919
JournalPLoS Neglected Tropical Diseases
Volume13
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Virus Diseases
Vaccines
Disease Outbreaks
Public-Private Sector Partnerships
Emerging Communicable Diseases
Mosquito Control
Alphavirus
Aedes
Licensure
Culicidae
Industry
Clinical Trials
Organizations
Chikungunya Fever

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Chikungunya as a paradigm for emerging viral diseases : Evaluating disease impact and hurdles to vaccine development. / Rezza, Giovanni; Weaver, Scott.

In: PLoS Neglected Tropical Diseases, Vol. 13, No. 1, 01.01.2019, p. e0006919.

Research output: Contribution to journalReview article

@article{b5f2db15fad44951a6298f9336489b78,
title = "Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development",
abstract = "Chikungunya fever (CHIKF) is an emerging infectious disease caused by an alphavirus transmitted by Aedes spp. mosquitoes. Because mosquito control programs are not highly efficient for outbreak containment, vaccines are essential to reduce the burden of disease. Although no licensed vaccine against CHIKF is yet available, many highly promising candidates are undergoing preclinical studies, and a few of them have been tested in human trials of phase 1 or 2. Here, we review recent findings regarding the need for a CHIKF vaccine and provide an update on vaccines nearing or having entered clinical trials. We also address needs to tackle bottlenecks to vaccine development-including scientific and financial barriers-and to accelerate the development of vaccines; several actions should be taken: (i) design efficacy trials to be conducted during the course of outbreaks; (ii) evaluate the opportunity for adopting the {"}animal rule{"}for demonstration of efficacy for regulatory purposes; (iii) strengthen the collective commitment of nations, international organizations, potential donors and industry; (iv) stimulate public and/or private partnerships to invest in vaccine development and licensure; and (v) identify potential markets for an effective and safe CHIKF vaccine.",
author = "Giovanni Rezza and Scott Weaver",
year = "2019",
month = "1",
day = "1",
doi = "10.1371/journal.pntd.0006919",
language = "English (US)",
volume = "13",
pages = "e0006919",
journal = "PLoS Neglected Tropical Diseases",
issn = "1935-2727",
publisher = "Public Library of Science",
number = "1",

}

TY - JOUR

T1 - Chikungunya as a paradigm for emerging viral diseases

T2 - Evaluating disease impact and hurdles to vaccine development

AU - Rezza, Giovanni

AU - Weaver, Scott

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Chikungunya fever (CHIKF) is an emerging infectious disease caused by an alphavirus transmitted by Aedes spp. mosquitoes. Because mosquito control programs are not highly efficient for outbreak containment, vaccines are essential to reduce the burden of disease. Although no licensed vaccine against CHIKF is yet available, many highly promising candidates are undergoing preclinical studies, and a few of them have been tested in human trials of phase 1 or 2. Here, we review recent findings regarding the need for a CHIKF vaccine and provide an update on vaccines nearing or having entered clinical trials. We also address needs to tackle bottlenecks to vaccine development-including scientific and financial barriers-and to accelerate the development of vaccines; several actions should be taken: (i) design efficacy trials to be conducted during the course of outbreaks; (ii) evaluate the opportunity for adopting the "animal rule"for demonstration of efficacy for regulatory purposes; (iii) strengthen the collective commitment of nations, international organizations, potential donors and industry; (iv) stimulate public and/or private partnerships to invest in vaccine development and licensure; and (v) identify potential markets for an effective and safe CHIKF vaccine.

AB - Chikungunya fever (CHIKF) is an emerging infectious disease caused by an alphavirus transmitted by Aedes spp. mosquitoes. Because mosquito control programs are not highly efficient for outbreak containment, vaccines are essential to reduce the burden of disease. Although no licensed vaccine against CHIKF is yet available, many highly promising candidates are undergoing preclinical studies, and a few of them have been tested in human trials of phase 1 or 2. Here, we review recent findings regarding the need for a CHIKF vaccine and provide an update on vaccines nearing or having entered clinical trials. We also address needs to tackle bottlenecks to vaccine development-including scientific and financial barriers-and to accelerate the development of vaccines; several actions should be taken: (i) design efficacy trials to be conducted during the course of outbreaks; (ii) evaluate the opportunity for adopting the "animal rule"for demonstration of efficacy for regulatory purposes; (iii) strengthen the collective commitment of nations, international organizations, potential donors and industry; (iv) stimulate public and/or private partnerships to invest in vaccine development and licensure; and (v) identify potential markets for an effective and safe CHIKF vaccine.

UR - http://www.scopus.com/inward/record.url?scp=85060179689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060179689&partnerID=8YFLogxK

U2 - 10.1371/journal.pntd.0006919

DO - 10.1371/journal.pntd.0006919

M3 - Review article

VL - 13

SP - e0006919

JO - PLoS Neglected Tropical Diseases

JF - PLoS Neglected Tropical Diseases

SN - 1935-2727

IS - 1

ER -